Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTFXKY7P)

• DOT Name: Small ribosomal subunit protein eS27 (RPS27)
• Synonyms: 40S ribosomal protein S27; Metallopan-stimulin 1; MPS-1
• Gene Name: RPS27
• Related Disease:
  Diamond-Blackfan anemia 6
  Gastric neoplasm
  Inborn error of metabolism
  Matthew-Wood syndrome
  Niemann-pick disease
  Blindness
  Brain disease
  Breast carcinoma
  Colon cancer
  Colon carcinoma
  Congenital nervous system disorder
  Diamond-Blackfan anemia
  Familial Alzheimer disease
  Gastric cancer
  Gaucher disease
  Hartnup disease
  Head-neck squamous cell carcinoma
  Hepatocellular carcinoma
  Hurler syndrome
  Hurler-Scheie syndrome
  Lymphoblastic lymphoma
  Lysosomal storage disease
  Malignant mesothelioma
  Medulloblastoma
  Mucopolysaccharidosis
  Mucopolysaccharidosis I
  Mucopolysaccharidosis II
  Mucopolysaccharidosis type 3A
  Mucopolysaccharidosis type 3B
  Mucopolysaccharidosis type 4A
  Neoplasm
  Plasma cell myeloma
  Stomach cancer
  Thyroid gland carcinoma
  Pancreatic ductal carcinoma
  Nervous system disease
  Adult glioblastoma
  Breast cancer
  Carcinoma of liver and intrahepatic biliary tract
  Cardiomyopathy
  Colorectal carcinoma
  Diamond-Blackfan anemia 17
  Fabry disease
  Glioblastoma multiforme
  Liver cancer
  Melanoma
  Small lymphocytic lymphoma
  Triple negative breast cancer
• UniProt ID: RS27_HUMAN
• PDB ID: 4UG0 ; 4V6X ; 5A2Q ; 5AJ0 ; 5FLX ; 5LKS ; 5OA3 ; 5T2C ; 5VYC ; 6FEC ; 6G18 ; 6G4S ; 6G4W ; 6G51 ; 6G53 ; 6G5H ; 6G5I ; 6IP5 ; 6IP6 ; 6IP8 ; 6OLE ; 6OLF ; 6OLG ; 6OLI ; 6OLZ ; 6OM0 ; 6OM7 ; 6QZP ; 6XA1 ; 6Y0G ; 6Y2L ; 6Y57 ; 6YBD ; 6YBW ; 6Z6L ; 6Z6M ; 6Z6N ; 6ZLW ; 6ZM7 ; 6ZME ; 6ZMI ; 6ZMO ; 6ZMT ; 6ZMW ; 6ZN5 ; 6ZOJ ; 6ZOK ; 6ZON ; 6ZP4 ; 6ZUO ; 6ZV6 ; 6ZVH ; 6ZVJ ; 6ZXD ; 6ZXE ; 6ZXF ; 6ZXG ; 6ZXH ; 7A09 ; 7K5I ; 7MQ8 ; 7MQ9 ; 7MQA ; 7QP6 ; 7QP7 ; 7R4X ; 7TQL ; 7WTS ; 7WTT ; 7WTU ; 7WTV ; 7WTW ; 7WTX ; 7WTZ ; 7WU0 ; 7XNX ; 7XNY ; 8G5Y ; 8G60 ; 8G61 ; 8G6J ; 8GLP ; 8JDJ ; 8JDK ; 8JDL ; 8JDM ; 8PPK ; 8PPL ; 8T4S
• Pfam ID: PF01667
• Sequence:
  MPLAKDLLHPSPEEEKRKHKKKRLVQSPNSYFMDVKCPGCYKITTVFSHAQTVVLCVGCS
  TVLCQPTGGKARLTEGCSFRRKQH
• Function: Component of the small ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. Required for proper rRNA processing and maturation of 18S rRNAs. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome.
• Tissue Specificity: Expressed in a wide variety of actively proliferating cells and tumor tissues.
• KEGG Pathway:
  Ribosome (hsa03010)
  Coro.virus disease - COVID-19 (hsa05171)
• Reactome Pathway:
  L13a-mediated translational silencing of Ceruloplasmin expression (R-HSA-156827)
  Peptide chain elongation (R-HSA-156902)
  SRP-dependent cotranslational protein targeting to membrane (R-HSA-1799339)
  Viral mRNA Translation (R-HSA-192823)
  Selenocysteine synthesis (R-HSA-2408557)
  Separation of Sister Chromatids (R-HSA-2467813)
  Resolution of Sister Chromatid Cohesion (R-HSA-2500257)
  RHO GTPases Activate Formins (R-HSA-5663220)
  Major pathway of rRNA processing in the nucleolus and cytosol (R-HSA-6791226)
  Mitotic Prometaphase (R-HSA-68877)
  Translation initiation complex formation (R-HSA-72649)
  Formation of a pool of free 40S subunits (R-HSA-72689)
  Formation of the ternary complex, and subsequently, the 43S complex (R-HSA-72695)
  Ribosomal scanning and start codon recognition (R-HSA-72702)
  GTP hydrolysis and joining of the 60S ribosomal subunit (R-HSA-72706)
  Eukaryotic Translation Termination (R-HSA-72764)
  Regulation of expression of SLITs and ROBOs (R-HSA-9010553)
  Response of EIF2AK4 (GCN2) to amino acid deficiency (R-HSA-9633012)
  EML4 and NUDC in mitotic spindle formation (R-HSA-9648025)
  SARS-CoV-1 modulates host translation machinery (R-HSA-9735869)
  SARS-CoV-2 modulates host translation machinery (R-HSA-9754678)
  Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) (R-HSA-975956)
  Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) (R-HSA-975957)
  Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal (R-HSA-141444)

Molecular Interaction Atlas (MIA) of This DOT

48 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Diamond-Blackfan anemia 6	DIS4FKKF	Definitive	Genetic Variation	[1]
Gastric neoplasm	DISOKN4Y	Definitive	Altered Expression	[2]
Inborn error of metabolism	DISO5FAY	Definitive	Biomarker	[3]
Matthew-Wood syndrome	DISA7HR7	Definitive	Altered Expression	[4]
Niemann-pick disease	DISKS5FO	Definitive	Biomarker	[5]
Blindness	DISTIM10	Strong	Biomarker	[6]
Brain disease	DIS6ZC3X	Strong	Genetic Variation	[7]
Breast carcinoma	DIS2UE88	Strong	Altered Expression	[8]
Colon cancer	DISVC52G	Strong	Biomarker	[9]
Colon carcinoma	DISJYKUO	Strong	Biomarker	[9]
Congenital nervous system disorder	DIS2BIP8	Strong	Biomarker	[10]
Diamond-Blackfan anemia	DISI2SNW	Strong	Biomarker	[11]
Familial Alzheimer disease	DISE75U4	Strong	Biomarker	[12]
Gastric cancer	DISXGOUK	Strong	Biomarker	[13]
Gaucher disease	DISTW5JG	Strong	Biomarker	[14]
Hartnup disease	DISYK0UH	Strong	Biomarker	[15]
Head-neck squamous cell carcinoma	DISF7P24	Strong	Biomarker	[16]
Hepatocellular carcinoma	DIS0J828	Strong	Biomarker	[9]
Hurler syndrome	DIS1DPSN	Strong	Biomarker	[3]
Hurler-Scheie syndrome	DIS1YJC5	Strong	Genetic Variation	[17]
Lymphoblastic lymphoma	DISB9ZYC	Strong	Biomarker	[18]
Lysosomal storage disease	DIS6QM6U	Strong	Genetic Variation	[19]
Malignant mesothelioma	DISTHJGH	Strong	Biomarker	[20]
Medulloblastoma	DISZD2ZL	Strong	Biomarker	[21]
Mucopolysaccharidosis	DISB083T	Strong	Genetic Variation	[22]
Mucopolysaccharidosis I	DISTS29G	Strong	Genetic Variation	[23]
Mucopolysaccharidosis II	DIS87GLG	Strong	Genetic Variation	[24]
Mucopolysaccharidosis type 3A	DIS2TLNF	Strong	Biomarker	[25]
Mucopolysaccharidosis type 3B	DIS1RN28	Strong	Biomarker	[26]
Mucopolysaccharidosis type 4A	DISTYFQS	Strong	Biomarker	[27]
Neoplasm	DISZKGEW	Strong	Biomarker	[28]
Plasma cell myeloma	DIS0DFZ0	Strong	Biomarker	[29]
Stomach cancer	DISKIJSX	Strong	Biomarker	[13]
Thyroid gland carcinoma	DISMNGZ0	Strong	Biomarker	[30]
Pancreatic ductal carcinoma	DIS26F9Q	moderate	Biomarker	[31]
Nervous system disease	DISJ7GGT	Disputed	Biomarker	[32]
Adult glioblastoma	DISVP4LU	Limited	Altered Expression	[8]
Breast cancer	DIS7DPX1	Limited	Altered Expression	[8]
Carcinoma of liver and intrahepatic biliary tract	DIS8WA0W	Limited	Biomarker	[33]
Cardiomyopathy	DISUPZRG	Limited	Biomarker	[32]
Colorectal carcinoma	DIS5PYL0	Limited	Altered Expression	[34]
Diamond-Blackfan anemia 17	DISSW8GN	Limited	Autosomal dominant	[1]
Fabry disease	DISUUQJF	Limited	Biomarker	[35]
Glioblastoma multiforme	DISK8246	Limited	Altered Expression	[8]
Liver cancer	DISDE4BI	Limited	Biomarker	[33]
Melanoma	DIS1RRCY	Limited	Biomarker	[34]
Small lymphocytic lymphoma	DIS30POX	Limited	Biomarker	[36]
Triple negative breast cancer	DISAMG6N	Limited	Biomarker	[37]

16 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Cisplatin	DMRHGI9	Approved	Cisplatin increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[38]
Estradiol	DMUNTE3	Approved	Estradiol decreases the expression of Small ribosomal subunit protein eS27 (RPS27).	[39]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Small ribosomal subunit protein eS27 (RPS27).	[40]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[41]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide affects the expression of Small ribosomal subunit protein eS27 (RPS27).	[42]
Selenium	DM25CGV	Approved	Selenium decreases the expression of Small ribosomal subunit protein eS27 (RPS27).	[43]
Benzatropine	DMF7EXL	Approved	Benzatropine increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[44]
Haloperidol	DM96SE0	Approved	Haloperidol increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[44]
Epigallocatechin gallate	DMCGWBJ	Phase 3	Epigallocatechin gallate increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[45]
Nabiximols	DMHKJ5I	Phase 3	Nabiximols increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[46]
Tocopherol	DMBIJZ6	Phase 2	Tocopherol decreases the expression of Small ribosomal subunit protein eS27 (RPS27).	[43]
PMID28460551-Compound-2	DM4DOUB	Patented	PMID28460551-Compound-2 increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[47]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the expression of Small ribosomal subunit protein eS27 (RPS27).	[49]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[50]
chloropicrin	DMSGBQA	Investigative	chloropicrin increases the expression of Small ribosomal subunit protein eS27 (RPS27).	[51]
AHPN	DM8G6O4	Investigative	AHPN decreases the expression of Small ribosomal subunit protein eS27 (RPS27).	[52]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 decreases the phosphorylation of Small ribosomal subunit protein eS27 (RPS27).	[48]
Coumarin	DM0N8ZM	Investigative	Coumarin increases the phosphorylation of Small ribosomal subunit protein eS27 (RPS27).	[48]

References

• [1] Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia. Br J Haematol. 2015 Mar;168(6):854-64. doi: 10.1111/bjh.13229. Epub 2014 Nov 25.
• [2] In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity.Clin Cancer Res. 2006 Aug 15;12(16):4965-73. doi: 10.1158/1078-0432.CCR-05-2316.
• [3] Mapping of IDUA gene variants in Pakistani patients with mucopolysaccharidosis type 1.J Pediatr Endocrinol Metab. 2019 Nov 26;32(11):1221-1227. doi: 10.1515/jpem-2019-0188.
• [4] Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.Br J Cancer. 2014 Oct 28;111(9):1780-7. doi: 10.1038/bjc.2014.460. Epub 2014 Aug 19.
• [5] Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience.J Pediatr. 2017 Nov;190:130-135. doi: 10.1016/j.jpeds.2017.06.048. Epub 2017 Jul 17.
• [6] AAV Gene Therapy for MPS1-associated Corneal Blindness.Sci Rep. 2016 Feb 22;6:22131. doi: 10.1038/srep22131.
• [7] Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.Mol Genet Metab. 2012 May;106(1):68-72. doi: 10.1016/j.ymgme.2012.02.003. Epub 2012 Feb 8.
• [8] Molecular mechanism of point mutation-induced Monopolar spindle 1 (Mps1/TTK) inhibitor resistance revealed by a comprehensive molecular modeling study.PeerJ. 2019 Jan 21;7:e6299. doi: 10.7717/peerj.6299. eCollection 2019.
• [9] Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.Molecules. 2018 Jun 20;23(6):1488. doi: 10.3390/molecules23061488.
• [10] Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.Mol Ther. 2004 Jun;9(6):866-75. doi: 10.1016/j.ymthe.2004.03.011.
• [11] Germline Genetic Predisposition to Hematologic Malignancy.J Clin Oncol. 2017 Mar 20;35(9):1018-1028. doi: 10.1200/JCO.2016.70.8644. Epub 2017 Feb 13.
• [12] Presenilin 1 Regulates [Ca(2+)]i and Mitochondria/ER Interaction in Cultured Rat Hippocampal Neurons.Oxid Med Cell Longev. 2019 Jul 28;2019:7284967. doi: 10.1155/2019/7284967. eCollection 2019.
• [13] Metallopanstimulin-1 regulates invasion and migration of gastric cancer cells partially through integrin 4.Carcinogenesis. 2013 Dec;34(12):2851-60. doi: 10.1093/carcin/bgt226. Epub 2013 Jun 26.
• [14] Investigation of newborns with abnormal results in a newborn screening program for four lysosomal storage diseases in Brazil.Mol Genet Metab Rep. 2017 Jul 4;12:92-97. doi: 10.1016/j.ymgmr.2017.06.006. eCollection 2017 Sep.
• [15] Long-term nonsense suppression therapy moderates MPS I-H disease progression.Mol Genet Metab. 2014 Mar;111(3):374-381. doi: 10.1016/j.ymgme.2013.12.007. Epub 2013 Dec 17.
• [16] Extraribosomal function of metallopanstimulin-1: reducing paxillin in head and neck squamous cell carcinoma and inhibiting tumor growth.Int J Cancer. 2010 Feb 1;126(3):611-9. doi: 10.1002/ijc.24791.
• [17] Deep Anterior Lamellar Keratoplasty in a Case of Hurler-Scheie Syndrome Undergoing Enzyme Replacement Therapy.Cornea. 2019 Mar;38(3):376-378. doi: 10.1097/ICO.0000000000001840.
• [18] Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress.Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13427-32. doi: 10.1073/pnas.1400892111. Epub 2014 Sep 2.
• [19] Neonatal screening for four lysosomal storage diseases with a digital microfluidics platform: Initial results in Brazil.Genet Mol Biol. 2018 Apr./Jun;41(2):414-416. doi: 10.1590/1678-4685-GMB-2017-0227. Epub 2018 Jun 4.
• [20] Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.
• [21] MPS1 kinase as a potential therapeutic target in medulloblastoma.Oncol Rep. 2016 Nov;36(5):2633-2640. doi: 10.3892/or.2016.5085. Epub 2016 Sep 12.
• [22] Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses.Mol Genet Genomic Med. 2019 May;7(5):e00617. doi: 10.1002/mgg3.617. Epub 2019 Mar 8.
• [23] Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications.Orphanet J Rare Dis. 2018 Jan 8;13(1):2. doi: 10.1186/s13023-017-0733-y.
• [24] Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.J Mol Med (Berl). 2017 Oct;95(10):1043-1052. doi: 10.1007/s00109-017-1562-0. Epub 2017 Jun 29.
• [25] Differences in maxillomandibular morphology among patients with mucopolysaccharidoses I, II, III, IV and VI: a retrospective MRI study.Clin Oral Investig. 2018 Apr;22(3):1541-1549. doi: 10.1007/s00784-017-2240-x. Epub 2017 Oct 18.
• [26] Targeting Heparan Sulfate Proteoglycans as a Novel Therapeutic Strategy for Mucopolysaccharidoses.Mol Ther Methods Clin Dev. 2018 Jun 18;10:8-16. doi: 10.1016/j.omtm.2018.05.002. eCollection 2018 Sep 21.
• [27] Free urinary glycosylated hydroxylysine as an indicator of altered collagen degradation in the mucopolysaccharidoses.J Inherit Metab Dis. 2020 Mar;43(2):309-317. doi: 10.1002/jimd.12166. Epub 2019 Oct 1.
• [28] Metallopanstimulin-1 (MPS-1) mediates the promotion effect of leptin on colorectal cancer through activation of JNK/c-Jun signaling pathway.Cell Death Dis. 2019 Sep 10;10(9):655. doi: 10.1038/s41419-019-1911-8.
• [29] Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3.Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):490-7. doi: 10.1016/j.clml.2011.06.015. Epub 2011 Sep 1.
• [30] Mps1 is associated with the BRAF(V600E) mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.Oncol Lett. 2018 Jun;15(6):9978-9986. doi: 10.3892/ol.2018.8561. Epub 2018 Apr 24.
• [31] Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.Mol Cancer Ther. 2014 Feb;13(2):307-315. doi: 10.1158/1535-7163.MCT-13-0324. Epub 2013 Nov 26.
• [32] Open issues in Mucopolysaccharidosis type I-Hurler.Orphanet J Rare Dis. 2017 Jun 15;12(1):112. doi: 10.1186/s13023-017-0662-9.
• [33] TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.Br J Pharmacol. 2017 Jun;174(12):1810-1825. doi: 10.1111/bph.13782. Epub 2017 Apr 22.
• [34] Mps1 is associated with the BRAF(V600E) mutation and predicts poor outcome in patients with colorectal cancer.Oncol Lett. 2019 Mar;17(3):2809-2817. doi: 10.3892/ol.2019.9924. Epub 2019 Jan 14.
• [35] Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy.J Inherit Metab Dis. 2018 Mar;41(2):209-219. doi: 10.1007/s10545-017-0098-3. Epub 2017 Nov 15.
• [36] Mitotic slippage: an old tale with a new twist.Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2.
• [37] Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.Eur J Med Chem. 2019 Aug 1;175:247-268. doi: 10.1016/j.ejmech.2019.04.047. Epub 2019 Apr 20.
• [38] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [39] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [40] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [41] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [42] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [43] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [44] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [45] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [46] Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.
• [47] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [48] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [49] Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
• [50] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [51] Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
• [52] ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood. 2004 Jan 1;103(1):194-207.